Boston Scientific Corp. (NYSE:BSX) slipped another shareholder’s lawsuit that accused the company of concealing problems stemming from its ill-fated 2006 buyout of Guidant Corp.
Legal News
BSX will pay big to the DOJ, Covidien loses bid in torcar war against AMR, Mela Sciences shares surge on FDA approval | MassDevice.com +3
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
Boston Scientific to pay $9 million to settle U.S. Justice Dept.’s Guidant probe
Boston Scientific Corp. (NYSE:BSX) will pay $9.25 million to settle allegations that the med-tech goliath’s Guidant subsidiary overcharged federal health care programs for medical devices.
The government accused Natick, Mass.-based Boston Scientific’s Guidant subsidiary with exaggerating the reliability of its pacemakers and defibrillators and then failing to grant credits to purchasers when the devices failed while still under warranty.
Covidien loses bid in trocar war with Applied Medical Resources
A federal judge in Texas “has a hard time” with arguments presented by Covidien plc (NYSE:COV) in its long-running patent spat with Applied Medical Resources over surgical trocars.
BSX to pay $9.25 million to settle accusations that it overcharged federal health programs
BSX’s CEO, Bard’s bids for Clearstream, Infuse’s lawsuits , AdvCellTech’s stem cell trail, NuVasive’s spat, BSX’s narrow escape and Mako’s Wall Street love made headlines this week | MassDevice.com +7
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Court calls for MDT’s safety data, Your medical records probably aren’t secure, Wright talks CEO salary details | MassDevice.com +3
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Infuse lawsuit: Judge orders Medtronic to produce safety data on bone growth protein
A federal judge ordered Medtronic Inc. (NYSE:MDT) to produce documents detailing the safety record of its controversial Infuse bone growth protein.
The shareholders’ lawsuit accuses the firm of artificially inflating its stock price with an off-label promotion scheme for a bone morphogenetic protein used in the Infuse device. Medtronic is weathering a spate of lawsuits over the product after a Spine Journal issue this summer revealed serious concerns about its safety.
Judge nixes J&J’s bid to sidestep a $482 million Cordis verdict | Legal News
It’s been a tough stretch in the courtroom for Johnson & Johnson’s (NYSE:JNJ) Cordis Corp.
The health care giant’s stent-making unit lost its bid for a new trial in the $482 million patent infringement lawsuit it lost to stent pioneer Dr. Bruce Saffran Tuesday.
That loss followed the failure of its bid to overturn a pair of U.S. Patent Office rules.
Judge nixes J&J’s bid to sidestep a $482 million Cordis verdict
It’s been a tough stretch in the courtroom for Johnson & Johnson’s (NYSE:JNJ) Cordis Corp.
The health care giant’s stent-making unit lost its bid for a new trial in the $482 million patent infringement lawsuit it lost to stent pioneer Dr. Bruce Saffran Tuesday.
That loss followed the failure of its bid to overturn a pair of U.S. Patent Office rules.
Cordis loses case against U.S. Patent Office
Cordis Corp., the stent-making arm of Johnson & Johnson (NYSE:JNJ), lost its legal challenge to a pair of U.S. Patent & Trademark Office rules because it filed the lawsuit too late, according to a ruling by a federal judge in Virginia.